dinaline has been researched along with ci 994 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| el-Beltagi, HM; Hagenbeek, A; Haroun, EA; Lelieveld, P; Martens, AC | 1 |
| Berger, MR; Seelig, MH | 1 |
| Corbett, TH; Foster, BJ; Jones, L; LoRusso, PM; Wiegand, R | 1 |
3 other study(ies) available for dinaline and ci 994
| Article | Year |
|---|---|
Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells--preclinical studies in a relevant rat model for human acute myelocytic leukemia.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Cell Survival; Clone Cells; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Drug Screening Assays, Antitumor; Hematopoietic Stem Cells; Leukemia, Myeloid, Acute; Male; Phenylenediamines; Rats; Rats, Inbred BN; Tumor Cells, Cultured | 1993 |
Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo and in vitro.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinogens; Colonic Neoplasms; Colorectal Neoplasms; Dimethylnitrosamine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Male; Phenylenediamines; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured | 1996 |
Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline).
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Area Under Curve; Benzamides; Blood Cell Count; Bone Marrow; Colonic Neoplasms; Drug Screening Assays, Antitumor; Female; Metabolic Clearance Rate; Mice; Phenylenediamines | 1997 |